<DOC>
	<DOC>NCT00636064</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery</brief_summary>
	<brief_title>A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery</brief_title>
	<detailed_description />
	<mesh_term>Valdecoxib</mesh_term>
	<mesh_term>Parecoxib</mesh_term>
	<criteria>Inclusion criteria: Patients expected to receive inhospital pain medication for pain after coronary artery bypass graft surgery for at least 3 full days and pain medication over a 10day period New York Heart Association Class I to III or cardiac ejection fraction of at least 35% before surgery Body mass index of less than or equal to 40 kg/m2 and weight of &gt;55 kg Patients scheduled to undergo an isolated (bypass grafting only without valve replacement, significant aortic reconstruction, or ventriculoplasty) primary CABG surgery via median sternotomy, using cardiopulmonary bypass Exclusion criteria: Patient has undergone or is going to have emergency coronary artery bypass graft surgery or surgery without cardiopulmonary bypass procedure Symptomatic peripheral vascular disease Heart attack within 48 hours of surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>